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With their almost unlimited potential for proliferation and differen-
tiation, human pluripotent stem cells (PSCs) and especially patient-
speciﬁc induced pluripotent stem cells (iPSCs) offer an unprecedentedtories for Biotechnology and
, Transplantation and Vascular
0625 Hannover, Germany.
artin).
. This is an open access article undercapacity of applications in medical research and clinical therapy. There-
fore, the ability to genetically modify PSCs is indispensable for their ap-
plication in disease modelling, drug screening or cellular therapies. For
introduction of transgenes into human PSCs a variety of methods has
been established including viral transduction, chemical transfection
and electroporation, and different vector types such as standard plas-
mids, artiﬁcial chromosomes, transposon elements or various viral
vectors can be applied. Thereby one has to distinguish between
“transient” introduction of transgenes that are lost over time, self-
replicative elements and approaches that lead to stable chromosomalthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Selectable key parameters for genome engineering in human PSCs. dsDNA, double
stranded DNA; ssODN, single strand oligonucleotide.
378 S. Merkert, U. Martin / Stem Cell Research 16 (2016) 377–386integration. In the latter case, either random integration of transgenic
elements or targeted insertion into known genomic sequences is
possible.
Conventional non-targeted transgene insertion using viral or
non-viral gene transfer technologies results in more or less random
integration, which bears the risk of insertional mutagenesis,
misregulated expression and transgene silencing (Hacein-Bey-
Abina et al., 2003). A more speciﬁc but elaborate alternative is the
classic technique of gene targeting, which uses the homologous re-
combination (HR) pathway and a donor plasmid carrying a select-
able transgene ﬂanked by homologous DNA stretches of substantial
length to speciﬁcally target the favoured locus. However, low
targeting efﬁciencies and challenging culture characteristics have
prevented classic gene targeting in human PSCs from becoming
broadly applicable, and positive and negative selection markers
have been indispensable to identify the rare events of targeting
among the typically more frequent off-target events.
This issue has been overcome by the discovery of targeted intro-
duction of a double strand break (DSB) strongly stimulating HR at
the breakpoint (Choulika et al., 1995; Johnson and Jasin, 2001;
Rouet et al., 1994). The recent advancement of customized
engineered endonucleases, including zinc-ﬁnger nucleases (ZFNs),
transcription activator-like effector nucleases (TALENs) or clus-
tered regularly interspaced short palindromic repeat (CRISPR)
RNA-guided nucleases, opens new perspectives for HR-based
strategies in human PSCs. These nucleases enable locus speciﬁc
introduction of DSBs, which can be repaired either by non-
homologous end joining (NHEJ) or by HR (Shrivastav et al., 2008),
thereby increasing the gene targeting efﬁciency by 100–10,000
fold (Cho et al., 2013; Durai et al., 2005; Miller et al., 2011; Porteus and
Carroll, 2005).
Within the last seven years, since the ﬁrst reports on designer nu-
cleases in human PSCs (Hockemeyer et al., 2009; Lombardo et al.,
2007; Zou et al., 2009), a rapid development and improvement in ge-
nome editing has been accomplished with numerous publications
successfully applying the technology. However, despite this abun-
dance of reports, it is still difﬁcult to choose the optimal methodolo-
gy for a speciﬁc application of interest. The different types of
designer nucleases have diverse characteristics concerning the
level of speciﬁcity, limitations regarding the choice of target
sequences, the complexity of the design and the expenditure of
time for manufacturing. Moreover, designer nucleases can be
introduced into the target cells via different technologies and can
be utilized in different ways by taking advantage of miscellaneous
cellular repair mechanisms and different types of donors for homol-
ogous recombination. Finally, comparable data concerning off-target
speciﬁcity, the background of non-targeted transgene integrations
and targeting efﬁciencies are rarely available, because different loci
in different cell types or cell lines were targeted. Moreover, a direct
comparison of targeting efﬁciencies is further complicated since
in most cases only the resulting numbers of targeted clones after
selection instead of primary targeting efﬁciencies are provided, and
levels of transfection-related cell death were typically not included
for calculation.
In the following we provide an overview on recent applications of
designer nucleases in human PSCs and on the diversity of possible
targeting and selection strategies (Supplemental Table 1). Thereby,
Fig. 1 highlights the key parameters which have to be considered be-
fore starting gene editing and which will be discussed here. Despite
the aforementioned limitations concerning a quantitative compari-
son of the published approaches, we will outline the most suitable
approaches for speciﬁc applications. In particular, the purpose of
this review is to present a practical guide, in terms of experimental
considerations, limitations and other critical aspects, for successful
gene editing in human PSCs using designer nucleases for various
applications.2. Choice and design of the nucleases
Fig. 2 brieﬂy illustrates the structure and characteristics of three
types of designer nucleases. In summary, ZFNs and TALENs consist of
target-speciﬁc DNA-binding domains fused to an unspeciﬁc nuclease
domain, whereby in the CRISPR/Cas9 system a chimeric RNA containing
the target sequence guides the Cas9 nuclease to cleave the DNA (Gaj
et al., 2013). The development and improvement of customized
engineered endonucleases is continuously progressing but efﬁciencies
and grade of speciﬁcity of the different nuclease systems are still contro-
versial. TALENs and the CRISPR/Cas9 systemhave already replaced ZFNs
as it is still technically challenging and time-consuming to engineer
active ZFNs and only a few academic labs have established routine
production (Maeder et al., 2008). The generation of TALENs is much
less labour-intensive and time-consuming once the system has been
established in the lab, although a typical TALEN requires ~1800 bp to
be assembled for each new target site. The CRISPR/Cas9 system is the
easiest to use, time-saving and relatively cheap, as the synthesis of an
only 20bpguide RNA is required to program the nuclease. Undoubtedly,
the production of several CRISPR guide RNAs for one genomic locus and
the validation of the most effective one is less time-consuming than
doing the same for TALENs. On the other hand, it has to be emphasized
that in both cases design, construction and preparation of the respective
plasmid vectors is usually the minor part of the entire targeting ap-
proach compared to the establishment of correctly targeted single cell
clones. In general, once the respective systems are established in a lab,
the construction can be accomplished in about two weeks for TALENs
and in one week for CRISPR/Cas9. Technical guidelines and different
TALEN assembly kits (https://www.addgene.org/talen/) as well as dif-
ferent CRISPR cloning systems (https://www.addgene.org/crispr/) are
available via Addgene or commercial sources. Online tools that facilitate
optimal design of such nucleases and their evaluation concerning efﬁ-
ciency and potential off-target activity can be found on https://tale-nt.
cac.cornell.edu/, https://bao.rice.edu/research/, http://www.rgenome.
net/cas-ofﬁnder/, http://www.genome-engineering.org/ or https://
chopchop.rc.fas.harvard.edu/index.php. However, previously validated
nucleases are already available from academic and commercial sources
formany genomic targets and the effort of designing new ones has to be
weighed.
After deﬁning the genomic target region, the respective individual
DNA sequence should be conﬁrmed to exclude single-nucleotide poly-
morphisms (SNPs) or other variations in the recognition site of the nu-
clease. Due to context-dependent interactions between neighbouring
zinc-ﬁngers, not all genomic sites can be targeted by ZFNs. In general,
one ZFN site can be found every 125–500 bp of a random genomic se-
quence, depending on the assembly method (Kim et al., 2009; Sander
et al., 2011; Sander et al., 2010). In contrast, TALENs can be designed
Fig. 2. Comparison of designer nucleases regarding recognition and cleavage mechanism, design requirements, duration of generation, efﬁciency and speciﬁcity. ZF, zinc-ﬁnger; PAM,
protospacer adjacent motif.
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5′ end of the DNA recognition site is required (Mak et al., 2012). In case of
the CRISPR guided Cas9 nuclease the presence of a protospacer adjacent
motif (PAM) sequence is necessary, which depends on the bacteria spe-
cies from which the Cas9 was derived (e.g. Streptococcus pyogenes
‘NGG’). The PAM sequence directly downstream of the target sequence
is not part of the guide RNA but is obligatory for cutting the DNA strand
(Jinek et al., 2012). Due to these sequence requirements, also the design
of TALENs and especially of the guide RNA of the CRISPR/Cas9 system
may reach limits. This is especially critical when using single stranded ol-
igonucleotides (ssODNs) with short homology arms, which can be
applied instead of donor plasmids for footprintless gene correction or
the integration of ﬂags or mutations at speciﬁc sites of a protein. Thus,
under some circumstances the nature of the genomic region as well as
the intended application determines the choice of the nuclease.
Apparently, high on-target efﬁciencies can be achieved with all
systems if suitable target sequences are available and optimal nucleases
are designed. Although all types of designer nucleases are guided by
nucleotide stretches homologous to the originally targeted genomic
sequence, strand breaksmay also be introduced at other DNA sequences
with a more or less high degree of homology to the targeted site.
Although such DNA strand breaks are rapidly repaired by cellular DNA
repair mechanisms, especially NHEJ may lead to the creation of single
nucleotide polymorphisms, small insertions or deletions, as well as
random insertion of transgenes at non-target sites. Such mutations
can functionally compromise the affected cell clone and may also result
in malignant transformation. Clearly, reduction of off-target activity
represents one of the major challenges in targeted genome engineering
especially if therapeutic application of the targeted cells is intended.
The primary determinant of the target speciﬁcity of an individual de-
signer nuclease is the length of its DNA recognition site, which is differ-
ent in ZFNs, TALENs and the CRISPR/Cas9 system. Also, the GC content
substantially inﬂuences the target speciﬁcity. In theory, a 16 bp recogni-
tion site should already be statistically unique in the human genome. In
reality, less than 50% of all 16-mer combinations are in fact unique and
recognition sequences of at least 18 bp should be preferred to achieve
hybridisation to a distinct locus (Li et al., 2015; Liu et al., 2008). In gen-
eral, TALENs can be expected to bind fewer off-target sequences than
ZFNs and CRISPR/Cas9, as the target speciﬁcity relies on a relativelylong recognitionmotif of 30–36 bp in lengthwhich is rarely found in ge-
nomes. In addition, ZFNs and TALENsmay be safer than the CRISPR/Cas9
system as they only act as a dimer, so that a pair of potential off-target
sites has to be located within a range of 100 bp to bring both FokI
nucleases close enough for activation.
For the CRISPR/Cas9 system with its 20 bp recognition sequence
signiﬁcant off-target mutagenesis in different human cell types could
be observed, indicating that the Cas9 nuclease can be active even at
sites withmultiple mismatched base pairs if they were not properly de-
signed (Fu et al., 2013; Hsu et al., 2013; Mali et al., 2013; Pattanayak
et al., 2013). In case of demonstrated off-target activity, the respective
imperfect target sequences were always followed by a suitable PAM
(Hsu et al., 2013), and PAM-proximal mismatches were less tolerated
than PAM-distal counterparts (Fu et al., 2013; Hsu et al., 2013; Mali
et al., 2013) suggesting for a 5–8 bp seed region. However, the overall
speciﬁcity was largely determined by the complete guide sequence in-
cluding the guide RNA architecture and dosage (Hsu et al., 2013;
Pattanayak et al., 2013). In contrast to various studies showing substan-
tial off-target damage at related sites when using common CRISPR/Cas9
systems, another study contradicted these ﬁndings since whole genome
sequencing of hPSC clones revealed low incidence of off-target mutations
after CRISPR/Cas9 mediated targeting (Veres et al., 2014). It is notewor-
thy, however, that insertions or deletions (INDELs) larger than 16 bp are
barely detectable using current Next-Generation Sequencing (NGS) tech-
nologies and might have been overseen in recent studies. It is likely that
much more off-target effects, which occurred in subpopulations of the
targeted cells, would be detectable in the targeted polyclonal cell popula-
tion, if more accurate sequencing systems than the applied “sequencing-
by-synthesis” technology (error rates per read between 10%, Illumina GA
IIx datasheet, and1% forHiSeq 2000 (Liu et al., 2012))would be used. Fur-
thermore, off-target mutations with frequencies below 1% or 0.1% would
only be detected by sequencing of 150 or 1500 single cell clones, respec-
tively (Tsai and Joung, 2014).
Very recently, two studies allowed detailed insights in the regulation
of Cas9 target searching and proofreading mechanisms before double
strand break induction (Knight et al., 2015; Sternberg et al., 2015).
Thus, the target search mechanism involves rapid three-dimensional
diffusion dynamics of Cas9 (Knight et al., 2015) and a ﬁnal checkpoint
beyond initial PAM recognition and RNA–DNA base pairing in terms of
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2015). This understanding will help to further limit off-target activity.
So far, for the reduction of off-target effects in CRISPR/Cas9 targeting
experiments, truncated gRNAs of 17–18 nt length or “enhanced speci-
ﬁcity” SpCas9 variants (Fu et al., 2014; Slaymaker et al., 2016) can be
applied without decreasing on-target efﬁciency. Another approach to
improve the speciﬁcity of the monomeric Cas9 nuclease, is the applica-
tion of paired Cas9 nickases to generate DNA DSBs. One nickase pro-
duces a single strand break only, and similar to ZFNs and TALENs the
targeted activity of two nickases leads to a double strand break that al-
lows engineering the respective site via NHEJ orHR. Since it is extremely
unlikely that a pair of nickases show an off-target activity at both com-
plementary strands of one genomic site, and because off-target single
strand breaks are repaired with high ﬁdelity by the base-excision repair
pathway instead of error prone NHEJ, the risk of off-site effects at geno-
mic sites where only one of the guide RNAs binds is dramatically re-
duced (Mali et al., 2013; Ran et al., 2013; Shen et al., 2014). Similar to
TALENs (Mussolino et al., 2011), also obligate heterodimeric FokI vari-
ants have been combined with the CRISPR system, which likewise im-
proves its speciﬁcity (Tsai et al., 2014). In view of the recent
contradictory studies and the ongoing development of improved
CRISPR/Cas9 systems further studies are clearly required to obtain a re-
liable comparative estimation of the off-target efﬁcacy of the different
types of designer nucleases. Certainly, reduction of off-target effects is
one major issue, especially for in vivo application. However, to date it
is still unclear if off-target effects will have a real impact on cell function
and cancerogenity since the enormous heterogeneity of the human ge-
nome makes prediction difﬁcult and biological read-outs are missing.3. Techniques to achieve appropriate expression of designer
nucleases in pluripotent stem cells
The technique of nuclease transfer into the cells is not only critical in
terms of efﬁciency but also with regard to safety issues, and has a pro-
found impact on the targeting efﬁciency. For appropriate nuclease ex-
pression most of the recent studies applied conventional expression
plasmids that were transfected via electroporation or nucleofection
(see Supplemental Table 1). In our experience, Neon™ transfection
works best and results in transfection efﬁciencies of up to 80% in most
human PSC lines (Merkert et al., 2014; Schwanke et al., 2014). Messen-
ger RNA or recombinant protein transfection as well as viral transduc-
tion through baculoviral or non-integrating lentiviral vectors have also
been successfully applied. Without induction of targeted double strand
breaks the likelihood of HR or NHEJ is extremely low, and apparently
only a small proportion of individual cells within the entire cell popula-
tion facilitates efﬁcient HR (see ‘Homologous recombination: donor
system and targeting strategy’ below). It is therefore of utmost impor-
tance to achieve high transfection/transduction efﬁciencies and tomax-
imize the proportion of cells that express signiﬁcant levels of nuclease
simultaneously with the presence of donor DNA. This is especially
important for targeting of genes, which are silent in the transfected
undifferentiated human PSCs. Donor DNA can be applied circular or
linearized and there are different opinions ofwhether this has an impact
on increasing random integration, transportability of the DNA into the
cell or precise recombination of the transgene. In general, plasmid size
should be kept as small as possible as large plasmids considerably de-
crease the transfection rates. In our experience, circular donor plasmids
of up to 7 kb usually work well, whereas for larger ones the transfection
efﬁciencies decrease substantially. Notably, the application of stable
human PSC lines already carrying a doxycycline-inducible Cas9 expres-
sion cassette within their AAVS1 locus (iCas9 PSCs) facilitated the
generation of double- and triple-gene knockout PSC lines or the intro-
duction of scarless speciﬁc genetic alterations since only small guide
RNAs and/or ssODNs had to be transfected into the cells (Gonzalez
et al., 2014).4. Gene knockout through non-homologous end joining
For the generation of gene knockouts in human PSCs gene targeting
without the use of donor DNA can be applied. Thereby, DSBs will be
repaired by the error-prone NHEJ pathway, which can lead to small
INDEL mutations. In general, NHEJ occurs at higher frequencies
compared to the precise HR pathway, which heavily depends on the
cell state, the genomic locus and the donor template. Therefore, NHEJ
is the more effective and simple method for the mediation of gene
knockouts because the generation of a donor plasmid is omitted. For
gene disruption through generation of INDELs within a coding exon,
the introduction of only one DSB is sufﬁcient, whereas bigger genomic
regions, e.g. whole genes, complete exons or microRNAs, can be deleted
by using multiple spanning nucleases. Efﬁcient gene inactivation
through error-prone NHEJ was, for example, used for the targeted
disruption of the HPRT1 gene (Frank et al., 2013) or for both alleles of
the DNA methyltransferase 3B (DNMT3B) gene (Horii et al., 2013). In
another study the generation of mutant alleles by NHEJ for 15 different
genes by TALENs and later for six genes with CRISPR/Cas9 targetingwas
investigated as ameans of performing rigorous diseasemodelling (Ding
et al., 2013a; Ding et al., 2013b). However, when using NHEJ for the
generation of gene knockouts one must be aware that the introduced
modiﬁcations will be random and inaccurate, because depending on
the genetic sequence, only the position of the DSB can be predicted. In
addition, the identiﬁcation and establishment of targeted cell clones
can be elaborate if the introduced knockout does not allow for selection
of targeted clones (for instance by FACS). Thus far, formost NHEJ knock-
out approaches an antibiotic or ﬂuorescence pre-selection of the
transfected cells has been applied to increase the initial targeted cell
population. For the introduction of precise genetic mutations or selec-
tion cassettes, however, the homology-directed repair is clearly the
method of choice.5. Homologous recombination: donor system and targeting strategy
Classic protocols for gene targeting through HR recommend the use
of donor plasmids containing a selection cassette between two homolo-
gous arms of several hundred up to several thousand bp. In addition to
antibiotic resistance markers for positive selection, the likelihood to se-
lect for clones with non-targeted (random) integration can be reduced
by placing negative selection markers such as herpes thymidine kinase
outside the homologous arms. The ratio of targeted to random integra-
tion in classic gene targeting approaches is very low, because HR
depends on the unlikely event of the homologous arms of the donor
vector invading the intact double strand of the corresponding counter-
parts in the genomic DNA. In contrast, the targeted double strand
break induced by designer nucleases strongly increases the probability
of HR with the frequency of random integration remaining unaltered.
As a result, the ratio of correctly targeted clones versus clones with ran-
dom integration is substantially shifted towards targeted integration
and negative selection is generally not required any more. Under opti-
mized conditions this ratio is even high enough to enable PCR screening
of targeted clones without any phenotypic selection. Targeted integra-
tion of transgenes usually requires monoallelic targeting, only. Howev-
er, full knockout of a speciﬁc gene typically requires biallelic targeting,
which can be achieved in a second round of genetic engineering or
even in a one-step approach. Interestingly, several recent publications
show an unexpected high proportion of cloneswhich underwent simul-
taneous targeting of both alleles. Given for instance a targeting frequen-
cy of 1% for one allele, onewould expect an efﬁciency of 0.01% for clones
with both alleles targeted. Instead, up to 50% of targeted clones can
show targeting of both alleles depending on the locus (Merkert et al.,
2014; Yusa et al., 2011; Zou et al., 2011b). The only explanation for
this ﬁnding is that only in a minor fraction of the total cell population
all molecular requirements are provided that generally enable HR. In
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substantial proportion of clones that underwent biallelic targeting.
Because of its inefﬁciency, the traditional laborious gene targeting
techniques have typically been used to produce deﬁned gene knockouts
or to integrate reporter genes under control of speciﬁc loci in the
genome of human (pluripotent stem) cell lines and mice. Designer
nucleases greatly facilitate such approaches as they are more efﬁcient,
more speciﬁc and less laborious, and they also offer the technique for
other applications such as the generation of transgene-overexpressing
cell lines. Furthermore, various novel applications in genome engineer-
ing that were as yet technically not feasible at all, now became possible
(Fig. 3).
One important application of designer nucleases in human PSCs is
the targeted integration of transgenes at speciﬁc genomic loci that
enable robust expression not only in undifferentiated cells but also in
the differentiated derivatives. So-called ‘safe harbour sites’ support
more or less stable levels of transgene expression from the external pro-
moters of choice and can be located intragenic in introns or extragenic.
They are considered as safe because integration of transgenes apparent-
ly does not lead to oncogenic transformation or show any signs of
genotoxic effects (Sadelain et al., 2012). As yet, the AAVS1 and CCR5
safe harbour loci are most frequently used, whereby the last one has
the attractive side effect of providing resistance of hematopoietic cell
lineages to HIV-transduction (Perez et al., 2008). According to own
experience, especially targeting of AAVS1 is highly efﬁcient in hPSCs
with relative targeting frequencies of more than 1% (Merkert et al.,
2014). Speciﬁc and efﬁcient TALENs as well as guide RNAs have been
published for both sites and can be obtained from academic sources or
can be designed accordingly. Although according to literature constitu-
tively expressed ﬂuorescence markers represent the most frequent
transgenes inserted into safe harbour sites, single cell cloning is in
most cases based on additional antibiotic resistance genes (see Sup-
plemental Table 1). Clearly, the application of selection cassettes
simpliﬁes the clone generation and is typically without adverse ef-
fects as long as the cell lines are not produced for later clinical use.
Regulated transgene expression from a safe harbour site can beFig. 3. Overview and description of possible applications of designer nucleases in human PS
knockouts. (C) Introduction of small modiﬁcations using ssODNs. DSB, double strand break; H
end-joining; PB, piggyBac; ssODNs, single strand oligonucleotides; 2A, self-cleaving peptide.achieved via inducible expression systems or tissue-speciﬁc promoters
enabling for example the isolation of speciﬁc cell populations (Gantz
et al., 2012; Hockemeyer et al., 2009; Qian et al., 2014; Tiyaboonchai
et al., 2014). Constitutive promoters provide reliable stable transgene
expression, e.g., allowing functional correction of genetic diseases
(Chang and Bouhassira, 2012; Zou et al., 2011b) or reporter gene-
based molecular imaging for transplantation experiments (Wang
et al., 2012). If a well-characterized promoter fragment is available,
even tissue- or cell type-speciﬁc transgene expression can be realized
from safe harbour loci. Due to the availability of established designer
nucleases and donor plasmids with homology arms for common safe
harbour loci, integration of potentially cell type-speciﬁc reporter
cassettes into such loci with subsequent testing of its speciﬁcity in
differentiated hPSC derivatives is often easily accomplished. If for a
given promoter fragment such an approach does not result in sufﬁcient
expression levels or adequate cell type-speciﬁcity, themuchmore labo-
rious strategy of integrating reporter or selection genes into an endoge-
nous gene locus of interest has to be considered. In this case, new
nucleases and donor plasmids for the respective locus typically have
to be generated. The design of both, nuclease and donor plasmid, criti-
cally depends on the question whether it is acceptable that one allele
of the affected gene is functionally destroyed or whether it is crucial
to maintain expression of both gene alleles. There are different possibil-
ities to preserve a functional genomic allele, like transgene integration
into intron sequences or the generation of fusion proteins. The latter
was applied for example for OCT4 reporter cell lines monitoring
the pluripotency state of hPSC cultures (Hockemeyer et al., 2009;
Hockemeyer et al., 2011; Hou et al., 2013). In our experience, reporter
gene integration replacing the endogenous stop codon in combination
with a self-cleaving 2A peptide is the approach of choice to maintain
the endogenous gene function. Fig. 4 illustrates the use of such a 2A
site which should result in the expression of both, the endogenous
and the reporter protein under control of the physiological promoter.
Finally, the decision for a speciﬁc targeting strategy always depends
on the transcriptional regulation of the gene of interest and the forma-
tion of different splice variants.Cs. (A) Gene correction and generation of transgenic cell lines. (B) Generation of gene
R, homologous recombination; INDELs, insertions or deletions; NHEJ, non-homologous
Fig. 4.Application of a 2A sequence for insertion of amarker genedownstreamof an endogenous gene results in two separate protein products after the translation process. The integration
of a marker gene replacing the endogenous stop codon in combination with a self-cleaving 2A peptide maintains the expression of both, the endogenous and the marker protein under
control of the physiological promoter. 2A, self-cleaving peptide sequence; GOI, gene of interest; hygro, hygromycin resistance; N, unknown nucleotide; loxP, recombination signal; pA,
polyadenylation signal; PGK, phosphoglycerate kinase promoter; Xaa, unknown amino acid.
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nucleases is the correction of disease-related mutations in endogenous
genes. Besides pure functional correction (for instance via overexpres-
sion of cDNA from a safe harbour locus) mutated endogenous genes
can also be directly corrected. Here, one can distinguish between
approaches leaving footprints of the targeting process and strategies
that restore the WT sequence without any further alterations in the
nucleotide sequence (Fig. 3A).
6. “Footprintless” gene editing
As in classic gene targeting, also most designer nuclease-based gene
correction approaches so far relied on the use of genetic selection cas-
settes for selection of correctly targeted clones. Such additional genetic
elements, even if located within intron sequences, may certainly inﬂu-
ence gene expression and regulation but can basically be removed
using the Cre/loxP or the Flp/FRT system. Importantly, both systems
do not work completely footprintless and leave a single loxP or FRT
site, respectively.
To date, various studies utilized the Cre/loxP and Flp/FRT systems for
(partial) excision of transgenes after targeted genomic integration. For
instance, several studies report on the integration of the wild type β-
globin sequence into the haemoglobin beta (HBB) gene of sickle cell dis-
ease iPSCs for genotypic correction, applying antibiotic selection and
subsequent excision of the utilized resistance cassette (Ma et al., 2013;
Sebastiano et al., 2011; Sun and Zhao, 2014; Zou et al., 2011a). Thereby
the cutting site and targeting strategy was determined by the type of
nuclease, leading to the integration of a ﬂoxed antibiotic resistant
cassette at different sites of the gene, which had a profound impact on
the success of the functional gene correction (Ma et al., 2013;
Sebastiano et al., 2011; Zou et al., 2011a). The integration into the ﬁrst
intron of HBB led only to partial restoration of the β-globin expression
even after Cre recombination (Sebastiano et al., 2011; Zou et al.,
2011a), whereby the integration downstream of the last exon could
restore the normal β-globin expression in differentiated erythrocytes
(Ma et al., 2013). Although remaining loxP or FRT sites may in many
cases not inﬂuence endogenous gene regulation, true footprintless
genomic restoration of wild type sequences in mutated genes still
represents the ultimate gene editing approach. The possibility to con-
duct such true footprintless gene editing became feasible for the ﬁrst
time with the development of the piggyBac (PB) transposon system.
Therefore, Sun and Zhao demonstrated the genetic correction of the
HBB genewithout leaving any residual ectopic sequences by a PB trans-
poson containing an antibiotic cassettewhichwas excised after targeted
integration (Sun and Zhao, 2014). The PB system requires anendogenous TTAA sequence and in contrast to the Cre/loxP and Flp/
FRT systems, the PB transposon fully restores its original insertion site
after excision— apparently at least inmost cases since one study detect-
ed imprecise excision in ~10% of events (Wang et al., 2008).
7. Gene editing using ssODNs as donors
Although a remaining loxP or FRT site may in many cases not inﬂu-
ence endogenous gene regulation, and the excision of a PB transposon in
most cases leads to restoration of the WT sequence, footprintless gene
correction using ssODNs as donors is considered as the more universal
and elegant approach. The possibility to correct disease-speciﬁc muta-
tions or to introduce speciﬁc mutations in patient-speciﬁc iPSCs pro-
vides entirely new opportunities in disease modelling, drug screening
and last but not least individualized cell therapies. IPSC lines engineered
in such ways represent perfect isogenic controls for in vitro assays and
screens, and may enable safe cellular therapies for many genetic dis-
eases. In addition to correction or insertion of mutations, homologous
recombination with ssODNs as donors also allows for the insertion of
short modiﬁcations such as protein tags or recombination sites into
endogenous loci where additional selective elements would be
unfavourable. Hence, for many purposes, the integration of small mod-
iﬁcations using designer nucleases and ssODNs without any selection
markers is the tool of choice. Therefore, Fig. 5 exemplarily illustrates
the workﬂow for a SNP conversion using ssODNs, recombinant Cas9
protein and in vitro transcribed guide RNA. Compared to antibiotic
selection-based targeting, a ssODN approach obviates time-consuming
donor plasmid generation and a second round of single cell cloning
after transgene excision. Furthermore, there is also the possibility for
enrichment of nuclease expressing cells via FACS if the transfected
vectors contain a ﬂuorescent reporter. In general, it can be expected
that the targeting efﬁciency is higher when using ssODNs due to a
higher amount of donor template in the cell which increases the likeli-
hood for pairing with genomic sequences. Furthermore, it is expected
that the sequence modulation by a ssODN is operative throughout the
whole cell cycle, in contrast to double stranded donors which enter
the classic HR pathways that are only active during the S and G2
phase of the cell cycle (Liu et al., 2010; Radecke et al., 2006; Schubert
et al., 2011). Meanwhile, several groups, including ourselves, have
shown selection-independent clone generation by using designer
nucleases and ssODNs in human PSCs (see Supplementary Table 1). In
some studies an initial cell sorting-based enrichment step of nuclease
expressing cells prior to subsequent PCR-based screening of the
enriched cell population was included (Ding et al., 2013a; Ding et al.,
2013b; Soldner et al., 2011)whereas others identiﬁed correctly targeted
Fig. 5.Exemplaryworkﬂow for SNP conversion using a donor ssODN, recombinant Cas9 protein and in vitro transcribed gRNA inhPSCs. For the genomic locus of interestﬁrst the researcher
has to design CRISPR target gRNAs (the PAM sequence is depicted in orange), an appropriate 120 bp ssODN and a screening primer pair for targeting analysis. After assembly and in vitro
transcription of the gRNAs, hPSCs can be transfected with Cas9 protein/gRNA complex and the ssODN. Targeting PCR analysis is performed on day 3 after transfection and generation of
single cell clones will be started. gRNA, guide RNA; N, unknown nucleotide; n, silent mutations for increased accuracy of the screening primer; SNP, single nucleotide polymorphism;
ssODN, single stranded oligonucleotide.
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2013). Miyaoka and colleagues applied the recently developed droplet
digital PCR (ddPCR) to capture even rare mutational events in order to
generate footprintless iPSC lines with precise mutations (Miyaoka
et al., 2014). Further improved targeting efﬁciencieswould considerably
facilitate selection-independent targeting approaches in PSCs. There-
fore, small molecules that effectively activate or block certain DNA re-
pair pathways can be used (Chu et al., 2015; Maruyama et al., 2015;
Yu et al., 2015).
For the design of the ssODNs we recommend a maximum length of
120 bp with two homology arms of 50 bp each, as illustrated in Fig. 5.
The total homology length should be at least 40 bp (Chen et al.,
2011a) and has to exactly match the target genomic sequence because
of its shortness. Thus, conﬁrmation of the respective genomic sequence
in the targeted cell line is essential prior to the design of the ssODN. In
addition to the base pairs of interest which are included in the ssODN,
we also recommend the integration of additional silentmutations to in-
crease the accuracy of a targeting speciﬁc primer for screeningpurposes.
In general, the diagnostic targeting PCR should run as robust as pos-
sible since it is the essential step for identifying targeted cell clones.
Thus, it is worth it to test different polymerases, primer pairs and PCR
conditions to assess the optimal settings. Of course, it is helpful to
have a positive control template for PCR establishment, but often
this is only available after successful targeting. Therefore we recom-
mend the analysis of the targeted cell population on day 2 or day 3
after transfection since this should deﬁnitely comprise targeting
events, if targeting was successful. Regardless, this primary analysis
should always be performed to decide whether it is worth it to con-
tinue with the elaborate limiting dilution and screening procedure.
During screening, the positive control is again essential to exclude
discarding false negative pools or clones due to PCR problems. For
the screening of hundreds of clones we also recommend the applica-
tion of cell lysis buffer which can be applied directly into the PCR
without elaborate genomic DNA isolation and any washing and pre-
cipitation steps. Direct PCR lysis reagents as well as the application of
polymerase reaction buffers including loading dyes substantially
simplify the entire screening process and considerably facilitate the
PCR-based screening process.8. Design of donor plasmids
If no footprintless gene targeting is required or it is intended to intro-
duce larger transgenes, donor plasmids have to be constructed that
contain the homology arms ﬂanking the transgenes or selection
cassettes coupled to promoters of choice. Similarly, donor plasmids
can be constructed to enable expression of a functional protein under
control of the natural endogenous locus. Clearly, the design of the
donor plasmid is of utmost importance for the success of the targeting
as well as the proper expression of the inserted genes. If possible, the
homology arms of the targeting vector should exactly match the
individual targeting sequence and should not be more than 40 bp
away from the double strand break site (Stark et al., 2004). Longer
distances can also work but will result in lower efﬁciency of HR, which
can be compensated for by the application of antibiotic selection
cassettes. We typically use homology arms as close as possible to the
break site and homology arms of about 500–800 bp on each site to
insert up to 9 kb into the genomic target site. In general, longer homol-
ogy arms may increase the chance for pairing with corresponding
genomic sequences but on the other hand lead to an increase in donor
plasmid size and lower transfection rates (see ‘Techniques to achieve
appropriate expression of designer nucleases in pluripotent stem
cells’). For the application of constitutive promoters in undifferentiated
human PSCs as well as in differentiated derivatives, we recommend the
CAG or PGK promoter, keeping in mind that the decision for an appro-
priate poly A signal is also of utmost importance for reliable gene ex-
pression. In our experience the RBG, BGH or HSV-TK poly A sites are
working properly in hPSCs and also in their differentiated counterparts.
In general, viral-derived elements like the CMVpromoter or SV40poly A
sites work less well in hPSCs and should be avoided if proper expression
in undifferentiated cells is intended. In order to minimize the plasmid
size, in case of simultaneous expression of more than one gene, we
suggest expression under control of a joint promoter through a short
self-cleaving 2A peptide instead of using an internal ribosomal entry
site (IRES), which is usually longer than 500 bp. In addition, the 2A
peptide enables stoichiometric expression ofmultiple proteins,whereas
the translation efﬁciency of a gene behind an IRES is much lower
compared to the gene in front (Ibrahimi et al., 2009; Kim et al., 2011).
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The last aspect we want to address in this review is the importance
of suitable cell culture conditions for targeting and single cell cloning
of human PSCs. This is probably the most challenging aspect since
there are signiﬁcant variances between different human PSC clones
concerning proliferation, transfection efﬁciency and single cell survival
during clone generation. Clearly, targeting via designer nuclease is
working quite well for many cell types but identiﬁcation and isolation
of targeted human single PSC clones often requires a lot of experience
in hPSC handling and practical training. In principle, you can use either
feeder-based or feeder-free approaches. Cultivation on feeder cells
highly supports single cell survival and, providing that feeder cell lines
expressing appropriate antibiotic resistance genes are available, is also
suitable for antibiotic selection. However, feeder cell preparation is
time-consuming and can be impractical for some applications. In addi-
tion, the use of murine feeder cells is deﬁnitely excluded when aiming
at the production of clinical-grade transgenic PSC lines. Dissociation of
PSCs growing as colonies on feeder cells for transfection or sorting
purposes may lead to higher rates of cell damage and death than disso-
ciation of cells grown under feeder-free conditions. In general, using
trypsin for human PSCs as well as multiple pipetting steps causing un-
necessary shear stress for the cells should be avoided. For feeder-free
cultivation, PSCs can be grown as monolayer cultures or in colonies on
matrices (Burridge et al., 2011; Chen et al., 2011b). Enzymatic (e.g.
Accutase) or enzyme-free passaging reagents (e.g. EDTA) can be used
in combination with feeder cell-conditioned culture medium, mTeSR
or E8 medium and one has to test which work best for each individual
PSC clone. Most commercially available media work quite well as long
as an appropriate cell density is applied and the Rho-associated
coiled-coil kinase (ROCK) inhibitor Y-27632 is added. However, the
cloning procedure becomes muchmore difﬁcult if single cell deposition
of human PSCs without feeder cells is intended. In this case, E8 media
(Chen et al., 2011b) and feeder cell- or PSC-conditioned cultivation
medium containing supporting paracrine factors work much better
than mTeSR media. Additionally, surface coating matrix proteins such
as laminin-521/E-cadherin (Rodin et al., 2014) or vitronectin (Chen
et al., 2011b) can also support the cloning efﬁciency. In general, suitable
culture conditions are dependent on the targeting strategy and have to
be adjusted individually for each PSC clone. For single cell cloning after
FACS or manual picking of clones after antibiotic selection, we recom-
mend seeding onto feeder cells, as the survival rate is oftenmuch better
compared to feeder-free conditions. In this case, typically the majority
of remaining cell clones ought to be targeted and the establishment of
only a few clones is sufﬁcient and easy to manage. Based on our experi-
ence, the establishment of human PSC clones using standard feeder cell
conditions is clearly the easiest way, since it enables the best morpho-
logical evaluation and monitoring of the stem cells. However, targeting
without any selection via limiting dilution requires PCR screening of
hundreds of single cell clones. Therefore, feeder cell based cultivation
is often unsuitable since the preparation of plates with feeder cells is
time-consuming and monolayer cultivation has clear advantages
concerning single cell dissociation and the splitting procedure. For
limiting dilution purposes it is also important to determine for each
individual PSC line the minimal number of cells per well required for
survival after single cell deposition. This typically varies from clone to
clone, and it may be required to seed an average of up to 20 cells
per well to enable cell survival. On the other hand, this may of course
require an additional round of cloning. In general, protocols and culture
conditions usually have to be adjusted to individual PSC clones
concerning the most appropriate culture conditions, the dissociation
procedure, the transfection approach and the cell densities after
reseeding. However, despite careful optimisation and individual adjust-
ment of these aspects, some PSC lines will still be more difﬁcult to
handle and successful targeted genome engineering will be more
demanding than in other lines.10. Conclusions
Gene targeting via designer nucleases in human PSCs is a powerful
method and enables a variety of applications for medical research.
There is continuous progress in the development of ZFNs, TALENs and
CRISPR-guided nucleases in terms of simplifying the design and assem-
bly, the improvement of speciﬁcity and the reduction of off-target activ-
ity. However, the more challenging parts of the application in human
PSCs are the efﬁcient transfection, gentle dissociation, as well as identi-
ﬁcation and establishment of targeted single cell clones. Especially for
laboratories with little human PSC experience this can be demanding
as successful targeting and clone generation is a result of cross-linked
interaction of various aspects. In this review we discussed all these
important aspects which might be helpful for starting gene targeting
in human PSCs, and tried to give useful practical recommendations. In
general, although selection-independent approaches require more
experience, they are advantageous, particularly in view of downstream
applications. Nevertheless, targeting strategies applying selection
cassettes and already approved designer nucleases seem feasible for
many labs, thus opening this seminal ﬁeld of research formany interest-
ed scientists.
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